For full-year 2024, preliminary net product revenues for Givlaari and Oxlumo were around $256 million and $167 million, respectively. ALNY's 2025 Pipeline Goals ...

Alnylam Pharmaceuticals ALNY focuses on developing novel therapeutics based on RNAi technology. The company’s pipeline of ...

Givlaari (givosiran) has been recommended as a treatment option for people aged 12 and over with AHP, a rare life-threatening genetic condition that causes attacks of severe abdominal pain ...

Givlaari, approved for the treatment of acute hepatic porphyria, recorded sales of $64.6 million, reflecting a year-over-year increase of 9% on a reported basis. Givlaari sales missed the Zacks ...

Alnylam’s marketed portfolio of drugs comprises Amvuttra (vutrisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Onpattro (patisiran). In the past year, shares of ALNY have surged 62% against ...